COMP <GO>
UTMD vs LLY // OPERATING MARGIN
Utah Medical Products Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: UTMD 3
— LLY 7
▲ OPERATING MARGIN LEADER: LLY
LAST: $66.80 (-2.96%) • MKT CAP: $212.7M
operating-margins
29.60%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTMD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTMD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.10% | 83.64% | -26.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.90% | 32.36% | -5.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.8x | 36.4x | -25.62 | UTMD | /valuation <GO> |
| Free Cash Flow Yield | 6.73% | 2.30% | +4.43 | UTMD | /fcf-yield <GO> |
| Operating Margin ACTIVE | 29.60% | 40.21% | -10.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | — | 31.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -5.80% | 45.51% | -51.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.87% | 0.49% | +1.38 | UTMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.2 | 66.6 | -39.40 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $212.7M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTMD REV | LLY REV | UTMD GROSS % | LLY GROSS % | UTMD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.5M | $65.18B | 57.1% | 83.0% | $14.3M | $16.81B |
| FY 2024 | $40.9M | $45.04B | 59.0% | 81.3% | $14.6M | $8.82B |
| FY 2023 | $50.2M | $34.12B | — | 79.3% | $22.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTMD // BETA —
LLY // BETA 0.51